Tag Archive

On day 1 of the World Stem Cells & Regenerative Medicine Congress, Keith Thompson, CEO of the Cell and Gene Therapy Catapult, announced, in partnership with the University of Aberdeen, the creation of a new company: Islexa. Islexa is developing an innovative method to produce laboratory grown islets, which are the organoids in charge of insulin production. This technology holds …

This year (2015) marks the tenth anniversary for the Terrapinn World Stem Cells & Regenerative Medicine Congress, but the question in my wind is how far has this industry travelled in those years. Returning to this conference for the third year and now with more than ten years involvement in the sector I hope to answer my own question over …

This May 20th, London will welcome over 60 leading international speakers to the 10th annual World Stem Cells & Regenerative Medicine Congress. Ahead of then we wanted to give you a taste of what you will hear on-site with some exclusive insights from these esteemed thought-leaders. Click here to read the full speaker interviews as part of the Industry Insights …

As news hits the stand that next May will see the ‘world’s first 3D-bioprinted organ transplantation’ take place with a thyroid gland, we take a look at a selection of other regeneration projects from across the globe that are working towards regenerating parts of the human body ahead of the tissue engineering and organ regeneration track at the World Stem …

Zami Aberman, Chairman and Chief Executive Officer, Pluristem joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress to present ‘Can cell therapy become the next generation of biological therapeutic product?’ Download this presentation now to find out: Can cell therapy become the next generation of biological therapeutic products? Cell therapy “must haves” to become the next biological …

Robert A. Preti, PhD, President, PCT; Chief Science Officer, NBS joined us at the 9th Annual World Stem Cells & Regenerative Medicine Congress ‘Understanding the path needed to bring your cell therapy to market.’ Download this presentation now to find out: What problem are we trying to solve? Development by Design (DbD) Quality by Design (QbD) Assembling a commercial manufacturing …